3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues. 1989

A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

A series of 2'- and 3'-fluorinated 2',3'-dideoxynucleosides and 3'-azido-2',3'-dideoxynucleosides were synthesized and evaluated for their inhibitory activity against human immunodeficiency virus-1 (HIV-1) replication in MT-4 cells. Neither conversion of 3'-fluoro- or 3'-azido-2',3'-dideoxyadenosine to the corresponding inosine derivatives nor 8-bromination of 2',3'-dideoxyadenosine resulted in increased anti-HIV-1 activity. Nor did introduction of a 2'-fluorine in the erythro or threo configuration lead to improved anti-HIV-1 activity of the parent 2',3'-dideoxynucleosides. 1-(2-Fluoro-2,3-dideoxy-beta-D-threo-pentofuranosyl)cytosine and 1-(2-fluoro-2,3-dideoxy-beta-D-erythropentofuranosyl)thymine were only marginally active. However, 3'-fluoro-2',3'-dideoxyuridine (FddUrd) proved to be potent and a relatively nontoxic inhibitor of HIV-1. 5-Halogenated derivatives of FddUrd were prepared in attempts to further increase its anti-HIV potency and selectivity. Of these 5-halogenated derivatives, 3'-fluoro-2',3'-dideoxy-5-chlorouridine emerged as the most selective inhibitor of HIV-1 replication. Its selectivity index was comparable to that of azidothymidine when evaluated under the same conditions.

UI MeSH Term Description Entries
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D055598 Chemical Phenomena The composition, structure, conformation, and properties of atoms and molecules, and their reaction and interaction processes. Chemical Concepts,Chemical Processes,Physical Chemistry Concepts,Physical Chemistry Processes,Physicochemical Concepts,Physicochemical Phenomena,Physicochemical Processes,Chemical Phenomenon,Chemical Process,Physical Chemistry Phenomena,Physical Chemistry Process,Physicochemical Phenomenon,Physicochemical Process,Chemical Concept,Chemistry Process, Physical,Chemistry Processes, Physical,Concept, Chemical,Concept, Physical Chemistry,Concept, Physicochemical,Concepts, Chemical,Concepts, Physical Chemistry,Concepts, Physicochemical,Phenomena, Chemical,Phenomena, Physical Chemistry,Phenomena, Physicochemical,Phenomenon, Chemical,Phenomenon, Physicochemical,Physical Chemistry Concept,Physicochemical Concept,Process, Chemical,Process, Physical Chemistry,Process, Physicochemical,Processes, Chemical,Processes, Physical Chemistry,Processes, Physicochemical

Related Publications

A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
January 2003, Nucleosides, nucleotides & nucleic acids,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
July 1988, Biochemical pharmacology,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
November 1967, Journal of medicinal chemistry,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
July 2011, Chemical biology & drug design,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
August 1987, Journal of medicinal chemistry,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
January 1999, Nucleosides & nucleotides,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
May 1980, Antimicrobial agents and chemotherapy,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
January 2002, Organic letters,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
January 1994, Journal of pharmaceutical sciences,
A Van Aerschot, and P Herdewijn, and J Balzarini, and R Pauwels, and E De Clercq
February 1989, Journal of medicinal chemistry,
Copied contents to your clipboard!